Contineum Therapeutics, Inc.
CTNM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001855175
In the last 90 days, Contineum Therapeutics, Inc. insiders filed 0 open-market purchases and 7 sales; 102 institutions reported holding it in 13F filings for Q2 2026, worth $500.6M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Contineum Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 7 filings
- 3 insiders, $1.07M in total
- Insiders trading
- 3
- Net value
- −$1.07M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Contineum Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Stengone Carmine N. | CEO and President | 17,217 | Sep 8, 2026 | 7 |
| Lorrain Daniel S. | Chief Scientific Officer | 135,202 | Jul 10, 2026 | 13 |
| Watkins Tim | CMO & Head of Development | 8,961 | Jul 1, 2026 | 4 |
| Ignelzi Troy A. | Director | – | Jun 26, 2026 | 1 |
| Boyce Sarah | Director | – | Jun 26, 2026 | 1 |
| Ware Olivia C | Director | – | Jun 26, 2026 | 1 |
| Lyons-Williams Lori | Director | – | Jun 26, 2026 | 1 |
| Schimmelpennink Evert B. | Director | – | Jun 26, 2026 | 1 |
| Brady Todd R. | Director | – | Jun 26, 2026 | 1 |
| Miralles Gines Diego | Director | – | Jun 26, 2026 | 1 |
| Slover Peter T | Chief Financial Officer | – | Jan 30, 2026 | 1 |
| Healy John Stephen | General Counsel and Corp Sec | – | Jan 30, 2026 | 1 |
| Huhn Stephen L. | CMO & Sr VP, Clinical Dev. | 12,800 | Jan 31, 2025 | 0 |
| Versant Ventures IV, LLC | 10% Owner | 148,312Indirect | Apr 11, 2024 | 0 |
| Versant Venture Capital IV, L.P. | 10% Owner | 148,312Indirect | Apr 11, 2024 | 0 |
| Versant Side Fund IV, L.P. | 10% Owner | 148,312Indirect | Apr 11, 2024 | 0 |
| Versant Venture Capital VI, L.P. | 10% Owner | 148,312Indirect | Apr 11, 2024 | 0 |
| Versant Vantage I, L.P. | 10% Owner | 148,312Indirect | Apr 11, 2024 | 0 |
| Versant Vantage I GP, L.P. | 10% Owner | 148,312Indirect | Apr 11, 2024 | 0 |
| Versant Ventures VI GP-GP, LLC | 10% Owner | 148,312Indirect | Apr 11, 2024 | 0 |
| Versant Vantage I GP-GP, LLC | 10% Owner | 148,312Indirect | Apr 11, 2024 | 0 |
| Versant Ventures VI GP, L.P. | 10% Owner | 148,312Indirect | Apr 11, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 (view filing)6:08 PM ET | Sep 8 | Same day | Stengone Carmine N.CEO and President | SSaleClass A Common Stock | −2.50K | $16.46 | −$41.1K | −12.7%17.2K after | 10b5-1 |
| Aug 3, 2026 (view filing)6:14 PM ET | Aug 3 | Same day | Stengone Carmine N.CEO and President | SSaleClass A Common Stock | −2.50K | $16.01 | −$40.0K | −12.7%17.2K after | 10b5-1 |
| Jul 10, 2026 (view filing)5:20 PM ET | Jul 8-9 | 2 days | Lorrain Daniel S.Chief Scientific Officer | SSaleClass A Common Stock | −1.04K | $16.00 | −$16.6K | −0.8%135.2K after | 2 lots10b5-1 |
| Jul 8, 2026 (view filing)6:49 PM ET | Jul 8 | Same day | Stengone Carmine N.CEO and President | SSaleClass A Common Stock | −2.50K | $16.00 | −$40.0K | −12.7%17.2K after | 10b5-1 |
| Jul 2, 2026 (view filing)5:47 PM ET | Jun 30-Jul 1 | 2 days | Lorrain Daniel S.Chief Scientific Officer | SSaleClass A Common Stock | −37.2K | $15.99 | −$594.6K | −21.6%135.2K after | 3 lots10b5-1 |
| Jul 1, 2026 (view filing)7:04 PM ET | Jun 30 | 1 day | Watkins TimCMO & Head of Development | SSaleClass A Common Stock | −10.8K | $16.02 | −$173.6K | −54.7%8.96K after | 10b5-1 |
| Jul 1, 2026 (view filing)7:04 PM ET | Jun 30 | 1 day | Stengone Carmine N.CEO and President | SSaleClass A Common Stock | −10.0K | $16.01 | −$160.1K | −36.7%17.2K after | 10b5-1 |
| Jun 1, 2026 (view filing) | Jun 1 | Same day | Lorrain Daniel S.Chief Scientific Officer | SSaleClass A Common Stock | −4.17K | $13.16 | −$54.9K | −2.9%139.4K after | 10b5-1 |
| May 1, 2026 (view filing) | May 1 | Same day | Lorrain Daniel S.Chief Scientific Officer | SSaleClass A Common Stock | −4.17K | $13.12 | −$54.7K | −2.8%143.5K after | 2 lots10b5-1 |
| Apr 6, 2026 (view filing) | Apr 6 | Same day | Lorrain Daniel S.Chief Scientific Officer | SSaleClass A Common Stock | −4.17K | $13.43 | −$56.0K | −2.7%147.7K after | 10b5-1 |
| Mar 2, 2026 (view filing) | Mar 2 | Same day | Lorrain Daniel S.Chief Scientific Officer | SSaleClass A Common Stock | −4.17K | $15.01 | −$62.6K | −2.7%151.9K after | 10b5-1 |
| Mar 2, 2026 (view filing) | Mar 2 | Same day | Watkins TimCMO & Head of Development | SSaleClass A Common Stock | −3.61K | $15.02 | −$54.2K | −100.0%0 after | 10b5-1 |
| Feb 26, 2026 (view filing) | Feb 24-25 | 2 days | Stengone Carmine N.CEO and President | SSaleClass A Common Stock | −7.10K | $16.02 | −$113.7K | −32.2%15.0K after | 2 lots10b5-1 |
| Feb 26, 2026 (view filing) | Feb 24-25 | 2 days | Lorrain Daniel S.Chief Scientific Officer | SSaleClass A Common Stock | −8.12K | $16.02 | −$130.2K | −4.9%156.1K after | 2 lots10b5-1 |
| Feb 20, 2026 (view filing) | Feb 19 | 1 day | Lorrain Daniel S.Chief Scientific Officer | SSaleClass A Common Stock | −100 | $16.00 | −$1.60K | −0.1%156.1K after | 10b5-1 |
| Feb 13, 2026 (view filing) | Feb 11 | 2 days | Stengone Carmine N.CEO and President | SSaleClass A Common Stock | −400 | $16.00 | −$6.40K | −2.6%15.0K after | 10b5-1 |
| Feb 13, 2026 (view filing) | Feb 11 | 2 days | Lorrain Daniel S.Chief Scientific Officer | SSaleClass A Common Stock | −400 | $16.00 | −$6.40K | −0.3%156.1K after | 10b5-1 |
| Feb 5, 2026 (view filing) | Feb 3 | 2 days | Lorrain Daniel S.Chief Scientific Officer | SSaleClass A Common Stock | −4.17K | $14.94 | −$62.3K | −2.6%156.1K after | 2 lots10b5-1 |
| Jan 30, 2026 (view filing) | Jan 28 | 2 days | Watkins TimCMO & Head of Development | SSaleClass A Common Stock | −3.61K | $14.18 | −$51.2K | −100.0%0 after | 2 lots10b5-1 |
| Jan 6, 2026 (view filing) | Jan 5 | 1 day | Lorrain Daniel S.Chief Scientific Officer | SSaleClass A Common Stock | −4.17K | $10.44 | −$43.5K | −2.5%160.2K after | 2 lots10b5-1 |
| Dec 30, 2025 (view filing) | Dec 29 | 1 day | Watkins TimCMO & Head of Development | SSaleClass A Common Stock | −3.61K | $12.06 | −$43.5K | −100.0%0 after | 10b5-1 |
| Dec 30, 2025 (view filing) | Dec 23 | 7 days | Lorrain Daniel S.Chief Scientific Officer | SSaleClass A Common Stock | −4.17K | $12.23 | −$51.0K | −2.5%164.4K after | 10b5-1 |
| Nov 27, 2024 (view filing) | Nov 25 | 2 days | Lorrain Daniel S.Chief Scientific Officer | SSaleClass A Common Stock | −1.01K | $16.02 | −$16.2K | −0.6%168.6K after | 10b5-1 |
| Nov 20, 2024 (view filing) | Nov 18 | 2 days | Lorrain Daniel S.Chief Scientific Officer | SSaleClass A Common Stock | −6.19K | $16.38 | −$101.4K | −3.5%169.6K after | 2 lots10b5-1 |